TAMOXIFEN CITRATE | N021807 | MAYNE PHARMA COMMERCIAL LLC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Shayna Showalter, MD | 84 | 2020-04-07 → 2026-06-01 | |
| Phase 3 | Active | Tolmar Inc. | 250 | 2021-07-01 → 2026-11-30 | |
| Phase 3 | Active | AstraZeneca | 5,511 | 2023-10-05 → 2037-05-06 | |
| Phase 3 | Active | Andrea DeCensi | 500 | 2008-11-12 → 2028-12-31 | |
| Phase 3 | Active | Astellas Pharma Global Development, Inc. | 982 | 2024-07-31 → 2028-04-30 | |
| Phase 3 | Active | Azienda Ospedaliero-Universitaria Careggi | 926 | 2021-02-08 → 2030-03-31 | |
| Phase 2 | Active | Haukeland University Hospital | 200 | 2016-04-15 → 2030-06 | |
| Phase 2 | Active | Northwestern University | 156 | 2020-02-17 → 2026-06-25 | |
| Phase 2 | Active | University of Chicago | 53 | 2019-11-25 → 2026-09-30 | |
| Phase 2 | Active | National Cancer Institute (NCI) | 81 | 2015-05-28 → 2027-02-02 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$506.49
Highest Price
$506.49
FSS NDCs
1
Big4 NDCs
0
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 51862-0682-01SOLTAMOX 10MG/5ML SOLN,ORAL | $506.49 | FSS | Mayne Pharma Commercial LLC | 07/14/2030 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
Total Spending
$525K
Total Claims
428
Beneficiaries
81
Avg Cost/Unit
$4.54
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.
5 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Apr 9, 2019 | SUPPL -6 | View Letter (PDF) |
| Oct 1, 2018 | SUPPL -5 | View Letter (PDF) |
| Nov 1, 2005 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.